U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C62H86N12O16
Molecular Weight 1255.4194
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DACTINOMYCIN

SMILES

[H][C@@]12CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)C3=C4N=C5C(OC4=C(C)C=C3)=C(C)C(=O)C(N)=C5C(=O)N[C@H]6[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@]7([H])CCCN7C(=O)[C@H](NC6=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C2=O)C(C)C

InChI

InChIKey=RJURFGZVJUQBHK-IIXSONLDSA-N
InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1

HIDE SMILES / InChI

Molecular Formula C62H86N12O16
Molecular Weight 1255.4194
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 10 / 10
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/1734954

Dactinomycin (actinomycin D) was isolated from Streptomyces by Selman Waksman in 1940s. The antibiotic shows anti-cancer activity; it was approved by FDA for the treatment of different cancer conditions among which are Ewing's sarcoma, Wilm's tumor, gestational trophoblastic disease, etc. Dactinomycin exerts its action by binding to DNA (preferably to GC motif) and thus inhibiting transcription.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
156.25 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
COSMEGEN

Approved Use

COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Launch Date

1964
Primary
COSMEGEN

Approved Use

COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Launch Date

1964
Primary
COSMEGEN

Approved Use

COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Launch Date

1964
Primary
COSMEGEN

Approved Use

COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Launch Date

1964
Primary
COSMEGEN

Approved Use

COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Launch Date

1964
Palliative
COSMEGEN

Approved Use

COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Launch Date

1964
Palliative
COSMEGEN

Approved Use

COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Launch Date

1964
Palliative
COSMEGEN

Approved Use

COSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Launch Date

1964
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
30.3 μg/mL
3 mg/kg single, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DACTINOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
35.5 ng/mL
1.5 mg/m² 1 times / day steady-state, intravenous
dose: 1.5 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DACTINOMYCIN plasma
Homo sapiens
population: UNHEALTHY
age:
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
142.4 mg × h/L
3 mg/kg single, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DACTINOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3.62 mg × min/L
1.5 mg/m² 1 times / day steady-state, intravenous
dose: 1.5 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DACTINOMYCIN plasma
Homo sapiens
population: UNHEALTHY
age:
sex: FEMALE / MALE
food status: UNKNOWN
12.8 mg × min/L
1.5 mg/m² 1 times / day multiple, intravenous
dose: 1.5 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
DACTINOMYCIN plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.8 h
3 mg/kg single, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DACTINOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
28.5 h
1.5 mg/m² 1 times / day steady-state, intravenous
dose: 1.5 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
DACTINOMYCIN plasma
Homo sapiens
population: UNHEALTHY
age:
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
3 mg/kg single, intravenous
dose: 3 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
DACTINOMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.15 mg/kg 1 times / day multiple, intravenous
Overdose
Dose: 0.15 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 0.15 mg/kg, 1 times / day
Sources:
unhealthy, 18 months
Health Status: unhealthy
Age Group: 18 months
Sex: M
Sources:
Other AEs: Pancytopenia, Mucositis...
Other AEs:
Pancytopenia (1 patient)
Mucositis (severe, 1 patient)
Pancreatitis (1 patient)
Hyponatremia (1 patient)
Hypocalcemia (1 patient)
Respiratory distress (1 patient)
Melena (1 patient)
Sources:
0.15 ug/kg multiple, intravenous
Highest studied dose
Dose: 0.15 ug/kg
Route: intravenous
Route: multiple
Dose: 0.15 ug/kg
Sources:
unhealthy, 40-77 years
Health Status: unhealthy
Age Group: 40-77 years
Sex: F
Sources:
1.5 mg/m2 single, intravenous
Highest studied dose
Dose: 1.5 mg/m2
Route: intravenous
Route: single
Dose: 1.5 mg/m2
Sources:
unknown, children
Health Status: unknown
Age Group: children
Sources:
AEs

AEs

AESignificanceDosePopulation
Hypocalcemia 1 patient
0.15 mg/kg 1 times / day multiple, intravenous
Overdose
Dose: 0.15 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 0.15 mg/kg, 1 times / day
Sources:
unhealthy, 18 months
Health Status: unhealthy
Age Group: 18 months
Sex: M
Sources:
Hyponatremia 1 patient
0.15 mg/kg 1 times / day multiple, intravenous
Overdose
Dose: 0.15 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 0.15 mg/kg, 1 times / day
Sources:
unhealthy, 18 months
Health Status: unhealthy
Age Group: 18 months
Sex: M
Sources:
Melena 1 patient
0.15 mg/kg 1 times / day multiple, intravenous
Overdose
Dose: 0.15 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 0.15 mg/kg, 1 times / day
Sources:
unhealthy, 18 months
Health Status: unhealthy
Age Group: 18 months
Sex: M
Sources:
Pancreatitis 1 patient
0.15 mg/kg 1 times / day multiple, intravenous
Overdose
Dose: 0.15 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 0.15 mg/kg, 1 times / day
Sources:
unhealthy, 18 months
Health Status: unhealthy
Age Group: 18 months
Sex: M
Sources:
Pancytopenia 1 patient
0.15 mg/kg 1 times / day multiple, intravenous
Overdose
Dose: 0.15 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 0.15 mg/kg, 1 times / day
Sources:
unhealthy, 18 months
Health Status: unhealthy
Age Group: 18 months
Sex: M
Sources:
Respiratory distress 1 patient
0.15 mg/kg 1 times / day multiple, intravenous
Overdose
Dose: 0.15 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 0.15 mg/kg, 1 times / day
Sources:
unhealthy, 18 months
Health Status: unhealthy
Age Group: 18 months
Sex: M
Sources:
Mucositis severe, 1 patient
0.15 mg/kg 1 times / day multiple, intravenous
Overdose
Dose: 0.15 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 0.15 mg/kg, 1 times / day
Sources:
unhealthy, 18 months
Health Status: unhealthy
Age Group: 18 months
Sex: M
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Polysaccharide Krestin enhances manganese superoxide dismutase activity and mRNA expression in mouse peritoneal macrophages.
2000
Actinomycin D and staurosporine, potent apoptosis inducers in vitro, are potentially effective chemotherapeutic agents against glioblastoma multiforme.
2000
VEGF expression in an osteoblast-like cell line is regulated by a hypoxia response mechanism.
2000 Apr
Testin induction: the role of cyclic 3',5'-adenosine monophosphate/protein kinase A signaling in the regulation of basal and lonidamine-induced testin expression by rat sertoli cells.
2000 Dec
Purinergic and adrenergic agonists synergize in stimulating vasopressin and oxytocin release.
2000 Dec 1
Mechanisms of GM-CSF increase by diesel exhaust particles in human airway epithelial cells.
2000 Jan
Carcinogenic nickel induces genes involved with hypoxic stress.
2000 Jan 1
Mimosine arrests cells in G1 by enhancing the levels of p27(Kip1).
2000 Jan 10
Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells.
2000 May 1
Experimental model of hepatic venoocclusive disease (VOD) caused by dactinomycin--preliminary report about hepatoprotective effect of amifostine.
2000 May-Jun
Venoocclusive liver disease (VOD) as a complication of Wilms' tumour management in the series of consecutive 206 patients.
2000 Oct
Transient posterior encephalopathy induced by chemotherapy in children.
2001 Feb
Polyphyenolics increase t-PA and u-PA gene transcription in cultured human endothelial cells.
2001 Feb
Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells.
2001 Feb
The effects of particulate wear debris, cytokines, and growth factors on the functions of MG-63 osteoblasts.
2001 Feb
Differential induction of stearoyl-CoA desaturase and acyl-CoA oxidase genes by fibrates in HepG2 cells.
2001 Feb 1
In vivo regulation of syndecan-3 expression in the rat uterus by 17 beta-estradiol.
2001 Jan 5
Differential induction of rat hepatic cytochromes P450 3A1, 3A2, 2B1, 2B2, and 2E1 in response to pyridine treatment.
2001 Mar
Oxidant stress induces gamma-glutamylcysteine synthetase and glutathione synthesis in human bronchial epithelial NCI-H292 cells.
2002 Apr
Effect of actinomycin D on simian rotavirus (SA11) replication in cell culture.
2002 Apr
Pathways of induction of peroxiredoxin I expression in osteoblasts: roles of p38 mitogen-activated protein kinase and protein kinase C.
2002 Apr 5
Induction and superinduction of 2,3,7,8-tetrachlorodibenzo-rho-dioxin-inducible poly(ADP-ribose) polymerase: role of the aryl hydrocarbon receptor/aryl hydrocarbon receptor nuclear translocator transcription activation domains and a labile transcription repressor.
2002 Aug 15
Phospholipase D activation by sphingosine 1-phosphate regulates interleukin-8 secretion in human bronchial epithelial cells.
2002 Aug 16
Interleukin 1beta induces functional prostaglandin E synthase in cultured human umbilical vein endothelial cells.
2002 Dec
Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
2002 Dec 1
Changes in gene expression linked to methamphetamine-induced dopaminergic neurotoxicity.
2002 Jan 1
Induction of MnSOD gene by arachidonic acid is mediated by reactive oxygen species and p38 MAPK signaling pathway in human HepG2 hepatoma cells.
2002 Jun 1
Functional analysis of MRP1 cloned from bovine.
2002 Jun 19
Heme oxygenase-1-derived carbon monoxide requires the activation of transcription factor NF-kappa B to protect endothelial cells from tumor necrosis factor-alpha-mediated apoptosis.
2002 May 17
Differential effects of thyroxine on metabolic enzymes and other macromolecules in a freshwater teleost.
2003 Apr 1
Induction of 1-cys peroxiredoxin expression by oxidative stress in lung epithelial cells.
2003 Aug
An efficient, nonenzymatic method for isolation and culture of murine aortic endothelial cells and their response to inflammatory stimuli.
2003 Jan-Feb
Synergy between sulforaphane and selenium in the induction of thioredoxin reductase 1 requires both transcriptional and translational modulation.
2003 Mar
Differential expression of c-fos and c-myc protooncogenes by estrogens, xenobiotics and other growth-stimulatory agents in primary rat hepatocytes.
2003 Mar
Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activation.
2003 Mar 15
Leiomyosarcoma of urinary bladder following cyclophosphamide therapy: report of two cases.
2003 May
Leptin induces increased alpha2(I) collagen gene expression in cultured rat hepatic stellate cells.
2003 May 15
Effects of hypoxia on monocyte inflammatory mediator production: Dissociation between changes in cyclooxygenase-2 expression and eicosanoid synthesis.
2003 Oct 3
Troglitazone inhibits cyclin D1 expression and cell cycling independently of PPARgamma in normal mouse skin keratinocytes.
2004 Dec
Veno-occlusive disease in pediatric patients receiving actinomycin D and vincristine only for the treatment of rhabdomyosarcoma.
2004 Dec
Overexpression of phospholipase D prevents actinomycin D-induced apoptosis through potentiation of phosphoinositide 3-kinase signalling pathways in Chinese-hamster ovary cells.
2004 Mar 1
Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism.
2004 Nov
Coordinated secretion of alkaline phosphatase into serum and intestine in fat-fed rats.
2004 Sep-Oct
Establishment and characterization of new cellular lymphoma model expressing transgenic human MDR1.
2005 Apr
Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells.
2005 Feb 10
Induction of thioredoxin reductase as an adaptive response to acrolein in human umbilical vein endothelial cells.
2005 Feb 25
Activation of peroxisome proliferator-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liver.
2005 Jan 14
Mechanism of TNF-{alpha} modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression.
2005 Mar
Mitochondrial redox state regulates transcription of the nuclear-encoded mitochondrial protein manganese superoxide dismutase: a proposed adaptive response to mitochondrial redox imbalance.
2005 Mar 1
Promoting insulin secretion in pancreatic islets by means of bisphenol A and nonylphenol via intracellular estrogen receptors.
2005 May
Patents

Sample Use Guides

Wilms’ Tumor, Childhood Rhabdomyosarcoma and Ewing’s Sarcoma: Regimens of 15 mcg/kg intravenously daily for five days administered in various combinations and schedules with other chemotherapeutic agents; Metastatic Nonseminomatous Testicular Cancer: 1000 mcg/m2 intravenously on Day 1 as part of a combination regimen with cyclophosphamide, bleomycin, vinblastine, and cisplatin; Gestational Trophoblastic Neoplasia: 12 mcg/kg intravenously daily for five days as a single agent. 500 mcg intravenously on Days 1 and 2 as part of a combination regimen with etoposide, methotrexate, folinic acid, vincristine, cyclophosphamide and cisplatin; Regional Perfusion in Locally Recurrent and Locoregional Solid Malignancies: 50 mcg (0.05 mg) per kilogram of body weight for lower extremity or pelvis, 35 mcg (0.035 mg) per kilogram of body weight for upper extremity.
Route of Administration: Intravenous
In Vitro Use Guide
Sources: www.ncbi.nlm.nih.gov/pubmed/25932119
Human osteosarcoma cell line MG63 were incubated with dactinomycin (actinomycin D) at final concentrations of 0.1, 0.5, 1 and 5 uM during 0, 2, 6 and 24 hours. The drug was shown to inhibit the proliferation of cells by decreasing cyclin gene transcriptions.
Substance Class Chemical
Created
by admin
on Wed Apr 02 07:33:17 GMT 2025
Edited
by admin
on Wed Apr 02 07:33:17 GMT 2025
Record UNII
1CC1JFE158
Record Status FAILED
Record Version
  • Download
Name Type Language
Actinomycin D
WHO-IP  
Preferred Name English
DACTINOMYCIN
HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
DACTINOMYCIN [HSDB]
Common Name English
ACTINOMYCIN C1
Common Name English
ACTINOMYCIN D [WHO-IP]
Common Name English
DACTINOMYCIN [WHO-IP]
Common Name English
3H-PHENOXAZINE-1,9-DICARBOXAMIDE, 2-AMINO-N,N'-BIS(HEXADECAHYDRO-6,13-DIISOPROPYL-2,5,9-TRIMETHYL-1,4,7,11,14-PENTAOXO-1H-PYRROLO(2,1-I)(1,4,7,10,13)OXATETRAAZACYCLOHEXADECIN-10-YL)-4,6-DIMETHYL-3-OXO-
Common Name English
ACTINOMYCIN-D
Common Name English
ACTINOMYCIN I1
Common Name English
DILACTONE ACTINOMYCIN D ACID
Common Name English
ACTINOMYCIN D [JAN]
Common Name English
DACTINOMYCIN [USP-RS]
Common Name English
GNF-PF-2290
Code English
DACTINOMYCIN [USP MONOGRAPH]
Common Name English
ACTINOMYCIN D [IARC]
Common Name English
DACTINOMYCIN [MART.]
Common Name English
DACTINOMYCIN [USAN]
Common Name English
DACTINOMYCIN [VANDF]
Common Name English
MERACTINOMYCIN
Common Name English
Dactinomycin [WHO-DD]
Common Name English
ACTINOMYCIN X1
Common Name English
DACTINOMYCINUM [WHO-IP LATIN]
Common Name English
DACTINOMYCIN [MI]
Common Name English
DACTINOMYCIN [ORANGE BOOK]
Common Name English
N,N'-((2-AMINO-4,6-DIMETHYL-3-OXO-3H-PHENOXAZINE-1,9-DIYL)-BIS(CARBONYLIMINO(2-HYDROXYPROPYLIDENE)CARBONYLIMINOISOBUTYLIDENECARBONYL-1,2-PYRROLIDINEDIYLCARBONYL(METHYLIMINO)METHYLENECARBONYL))BIS(N-METHYL-L-VALINE) DILACTONE
Common Name English
NSC-3053
Code English
NCI-C04682
Code English
ACTINOMYCIN IV
Common Name English
dactinomycin [INN]
Common Name English
ONCOSTATIN K
Common Name English
COSMEGEN
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C204
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
NDF-RT N0000000233
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
LIVERTOX NBK548778
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
IARC Actinomycin D
NDF-RT N0000000150
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
NDF-RT N0000180850
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
WHO-ATC L01DA01
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
WHO-VATC QL01DA01
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
Code System Code Type Description
RS_ITEM_NUM
1162400
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
PRIMARY
HSDB
3220
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
PRIMARY
PUBCHEM
457193
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
PRIMARY
DRUG BANK
DB00970
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
PRIMARY
MERCK INDEX
m4067
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
PRIMARY Merck Index
LACTMED
Dactinomycin
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
PRIMARY
EVMPD
SUB129914
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
PRIMARY
CAS
50-76-0
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
PRIMARY
FDA UNII
1CC1JFE158
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
PRIMARY
NCI_THESAURUS
C412
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-063-6
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
PRIMARY
EPA CompTox
DTXSID9020031
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
PRIMARY
DAILYMED
1CC1JFE158
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DACTINOMYCIN
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
PRIMARY Description: An orange-red to red, crystalline powder.Solubility: Soluble in water at 10 ?C and slightly soluble in water at 37 ?C; freely soluble in ethanol (~750 g/l) TS and methanol R;very slightly soluble in ether R.Category: Cytotoxic drug.Storage: Dactinomycin should be kept in a tightly closed container, protected from light, and stored at a temperature notexceeding 40 ?C.Additional information: Dactinomycin is hygroscopic and is affected by light and heat.CAUTION: Dactinomycin must be handled with care, avoiding contact with the skin and inhalation of airborne particles.
EVMPD
SUB13528MIG
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
PRIMARY
CHEBI
27666
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
PRIMARY
MESH
D003609
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
PRIMARY
ChEMBL
CHEMBL1554
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
PRIMARY
SMS_ID
100000085032
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
PRIMARY
INN
1155
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
PRIMARY
RXCUI
3100
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
PRIMARY RxNorm
WIKIPEDIA
Dactinomycin
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
PRIMARY
DRUG CENTRAL
774
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
PRIMARY
NSC
3053
Created by admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
PRIMARY
Related Record Type Details
BINDER->LIGAND
BINDING
TRANSPORTER -> SUBSTRATE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC